Oncology
Ivonescimab Improves Survival in Squamous NSCLC Trial
In China’s phase 3 HARMONi-6 trial, ivonescimab plus chemotherapy improved interim overall survival versus tislelizumab plus chemotherapy in advanced squamous NSCLC.
Rayan Salih · September 2, 2026 · 6 min